Cilostazol treatment of claudication in diabetic patients

Current Medical Research and Opinion

Volumn 18, Issue 8, 2002, Pages 479-487

  Rendell, Marc ^a   Cariski, Alan T ^b   Hittel, Norbert ^c   Zhang, Peter ^b  

^a Creighton Diabetes Center   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c Otsuka Frankfurt Research Institute GmbH   (Germany)

Author keywords

Absolute claudication distance; Cilostazol; Diabetes; Intermittent claudication; Peripheral arterial disease

Indexed keywords

CILOSTAZOL; INSULIN; PLACEBO;

ABSOLUTE CLAUDICATION DISTANCE; ADULT; AGED; ARTICLE; BLEEDING; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; STANDARD; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TREADMILL EXERCISE; WALKING;

ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PLACEBOS; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0036969555     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001245     Document Type: Article

References (36)

1. Barnes RW. Vascular holism: the epidemiology of vascular disease. Ann Vasc Surg 1995;9:576-82
2. Balkau B, Vray M, Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol 1994;23(Suppl 3):8-16
3. Clement DL, Boccalon H, Dormandy J, Durand-Zalenski I, Fowkes G, Brown T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol 2000;19:97-125
4. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6
5. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81
6. Fowkes FGR, Housley E, Cawood EHH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92
7. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49
8. Dormandy J, Heeck L, Vig S. Intermittent claudication: a condition with underrated risks. Semin Vasc Surg 1999;12:96-108
9. Carman TL, Fernandez BB. A primary care approach to the patient with claudication. Am Fam Physician 2000;61:1028-32
10. Zeltsman D, Kerstein MD. Sociology of care in patients with severe peripheral vascular disease. Am Surg 1998;64:175-7
11. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association, September 18-20, 1992, New Orleans, Louisiana. Circulation 1993;88:819-28
12. Morgan CL, Currie CJ, Stott NC, et al. The prevalence of multiple diabetes-related complications. Diabet Med 2000;17:146-51
13. Katsumori K, Wasada T, Kuroki H, et al. Prevalence of macro and microvascular diseases in non-insulin-dependent diabetic and borderline glucose-intolerant subjects with insulin resistance syndrome. Diabetes Res Clin Pract 1995;29:195-201
14. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. JAMA 1995;274:975-80
15. Gibellini R, Fanello M, Bardile AF, et al. Exercise training in intermittent claudication. Int Angiol 2000;19:8-13
16. Regensteiner JG, Meyer TJ, Krupski WC, et al. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997;48:291-300
17. Whitehill TA. Role of revascularization in the treatment of claudication. Vasc Med 1997;2:252-6
18. Powell RJ, Fillinger M, Bettmann M, et al. The durability of endovascular treatment of multisegment iliac occlusive disease. J Vasc Surg 2000;31:1178-84
19. Karch LA, Mattos MA, Henretta JP, et al. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg 2000;31:880-7
20. Sayers RD, Raptis S, Berce M, Miller JH. Long-term results of femorotibial bypass with vein or polytetrafluoroethylene. Br J Surg 1998;85:934-8
21. Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995;274:165-71
22. Heer R, Walker S, MacSweeney, S. The effects of sublingual glyceryl trinitrate on walking distance in patients with intermittent claudication. A randomised, doubled-blind, placebo-controlled, cross-over study. Curr Med Res Opin 2001;17:113-16
23. Elam MB, Heckman JR, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942-7
24. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86
25. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74
26. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50
27. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30
28. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters J. The prevalence of multiple diabetes-related complications. Diabet Med 2000;17:146-51
29. TASC Working Group. Management of PAD (peripheral arterial disease): TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 pt 2, Suppl):S1-S296
30. Boyko EJ, Ahroni JH, Davignon D, et al. Diagnostic utility of the history and physical examination for peripheral vascular disease among patients with diabetes mellitus. J Clin Epidemiol 1997;50(6):659-88
31. Jonason T, Ringqvist I. Diabetes mellitus and intermittent claudication. Relation between peripheral vascular complications and location of the occlusive atherosclerosis in the legs. Acta Med Scand 1985:218:217-21
32. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 1989;38(4):504-9
33. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787-800
34. Reilly MP, Mohler ER. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56
35. Igawa T, Tani T, Chijiwa T, et al. Potentiation of anti platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-23
36. Omoto S, Nomura S, Shouzu A, et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 1999;81:271-7